Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Hunault

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
European Journal of Haematology|April 18, 2020
R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory studyCarole Lacout, Corentin Orvain, Valérie Seegers, et al.
European Journal of Haematology|July 15, 2018
Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantationAnne Bouvier, Bénédicte Ribourtout, Sylvie François, et al.
British Journal of Haematology|May 16, 2019
Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspotsAnnaëlle Beucher, Mammoun Dib, Corentin Orvain, et al.
Blood Cancer Journal|May 26, 2018
Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trialJérôme Paillassa, Thibaut Leguay, Xavier Thomas, et al.
Haematologica|December 7, 2007
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trialMathilde Hunault, Malgorzata Truchan-Graczyk, Denis Caillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemiaPatrice Chevallier, Jacques Delaunay, Pascal Turlure, et al.
Annals of Hematology|August 10, 2018
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphomaJonathan Farhi, Kamel Laribi, Corentin Orvain, et al.
British Journal of Haematology|July 29, 2025
Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapyCoralie Mallebranche, Carole Mosnier, Corentin Orvain, et al.
American Journal of Hematology|September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO StudyCorentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
European Journal of Haematology|April 18, 2020
R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: A eight-year trajectory studyCarole Lacout, Corentin Orvain, Valérie Seegers, et al.
European Journal of Haematology|July 15, 2018
Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantationAnne Bouvier, Bénédicte Ribourtout, Sylvie François, et al.
British Journal of Haematology|May 16, 2019
Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspotsAnnaëlle Beucher, Mammoun Dib, Corentin Orvain, et al.
Blood Cancer Journal|May 26, 2018
Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trialJérôme Paillassa, Thibaut Leguay, Xavier Thomas, et al.
Haematologica|December 7, 2007
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trialMathilde Hunault, Malgorzata Truchan-Graczyk, Denis Caillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemiaPatrice Chevallier, Jacques Delaunay, Pascal Turlure, et al.
Annals of Hematology|August 10, 2018
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphomaJonathan Farhi, Kamel Laribi, Corentin Orvain, et al.
British Journal of Haematology|July 29, 2025
Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapyCoralie Mallebranche, Carole Mosnier, Corentin Orvain, et al.
American Journal of Hematology|September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO StudyCorentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Pageof 13